7 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets (COMPACT)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,
Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from more patient-friendly routes of administration. Moreover, new classes of BP (e.g. siRNA, miRNA, DARPins) with specificity for intracellular targets hold promise but await the advent of efficient delivery systems before their potential can be realised into ther ...
Voir le projet
22
Participants partenaires
TERMINÉ
DARPin Targeted Magnetic Hyperthermic Therapy for Glioblastoma (DARTRIX)
Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,
"DARTRIX, ‘DARPin Targeted RX (therapy)’ is a multidisciplinary collaborative project that will develop high-affinity protein scaffolds to create a new generation of targeted therapeutics for the treatment of glioblastoma. There is great need; glioblastoma is virtually incurable and most patients die within 12 months of diagnosis. DARPins are small, non-immunoglobulin human protein scaffolds that ...
Voir le projet
8
Participants partenaires
TERMINÉ
General light triggered switches and sensors for studying proteins inside the cell (NEXTBINDERS)
Date du début: 1 mai 2011, Date de fin: 30 avr. 2016,
"The overall objective is to develop general strategies for creating sensors and switches that work inside cells. They will be engineered from Designed Ankyrin Repeat Proteins (DARPins) as general binding proteins that function inside cells and can be generated against any target by selection and directed evolution. Light-triggered switches will be engineered by placing a LOV domain from phototrop ...
Voir le projet
1
Participant partenaire
TERMINÉ
Protein Binders for Characterisation of Human Proteome Function: Generation, Validation, Application (AFFINOMICS)
Date du début: 1 avr. 2010, Date de fin: 31 mars 2015,
The Affinomics programme aims to leverage existing efforts in Europe to generate large-scale resources of validated protein-binding molecules (‘binders’) as affinity reagents for characterisation of the human proteome and to apply them in comprehensive structural and functional analyses of protein expression, interactions and complexes. Proteome targets will be focused on five categories of inter- ...
Voir le projet
20
Participants partenaires
TERMINÉ
Lessons from the genome of Escherichia coli: understanding heterologous expression of eukaryotic internal membrane proteins in bacterial cells (BioIMPrOve)
Date du début: 1 déc. 2012, Date de fin: 30 nov. 2014,
Eukaryotic cells express integral membrane proteins (IMP) that exchange substances with their environment or receive signals in the form of small molecules, peptides or proteins. Most human IMPs are inherently difficult to study, because of complications in obtaining adequate amounts of stable and functional proteins. G protein-coupled receptors (GPCRs) are the largest IMP family in the human geno ...
Voir le projet
1
Participant partenaire
TERMINÉ
Advanced affinity tools and technologies for high throughput studies of the human proteome (AffinityProteome)
Date du début: 1 mars 2009, Date de fin: 29 févr. 2012,
High specificity affinity reagents (‘binders’) are essential probes for proteome research, enabling the detection and localisation of multiple proteins in tissues and fluids in health and disease, through the application of binder-based technologies (affinity proteomics). This proposal links the high throughput production of quality-controlled, recombinant binding molecules of different types (ant ...
Voir le projet
10
Participants partenaires
TERMINÉ
Conversion of integral membrane receptors into soluble forms (GPCRs)
Date du début: 1 sept. 2009, Date de fin: 31 août 2011,
G-protein coupled receptors (GPCRs) are cell surface receptors that mediate the cellular responses to an enormous diversity of endogenous signaling molecules as well as environmental signals. GPCRs are a major target for the pharmaceutical industry as is reflected by the fact that more than 50% of all medicines available today act on a GPCR and represent about a quarter of the top-selling drugs wo ...
Voir le projet